Da dasatinib primært metaboliseres i leveren, forventes optagelsen af dasatinib at øges, hvis leverfunktionen er nedsat.
Since dasatinib is mainly metabolised through the liver, exposure to dasatinib is expected to increase if liver function is impaired.